Femme et Homme
- | Pays :
- Spain
- United States
- | Organes : -
- | Spécialités : -
Extrait
Phase I multicenter, open-label, dose-escalating clinical and pharmacokinetic trial of PM02734 administered in combination with erlotinib to determine the safety and tolerability and to identify the dose limiting toxicity (DLT) and the recommended dose (RD) of the combination of PM02734 and erlotinib, in patients with advanced malignant solid tumors.
Critère d'inclusion
- Advanced Malignant Solid Tumors